Mandate

Vinge advises Irisity AB in connection with the acquisition of Ultinous and a directed share issue

Vinge advises Irisity AB in connection with the acquisition of Ultinous and a directed share issue

Vinge advises Irisity AB (publ) in connection with the acquisition of Ultinous Zrt., a Swedish-Hungarian AI inventor, for a consideration of SEK 45 million, on a cash and debt free basis and assuming normalized working capital, which will be paid through an issue in kind entailing 9,000,000 new shares in Irisity at a subscription price of SEK 5.00 per share. In conjunction with the Acquisition Stockhorn Capital AB (founded by Gustav Andersson and Inna Kaushan) will invest SEK 45 million in Irisity through a directed share issue on the same terms as in the In-kind Issue, i.e., SEK 5.00 per share. The transaction will be subject to national FDI Regulation requiring approval from Swedish and Hungarian authorities and Iristy's EGM resolving to authorize the board of directors to resolve on the share issues. As part of the acquisition and directed share issue, Irisity and Stockhorn Capital will also enter into a loan agreement pursuant to which Stockhorn Capital will lend Irisity an amount of SEK 15 million.

Vinge's team consists of Anders Strid, Edin Agic and Fredrik Löwenclou.

Related

Vinge has advised Verisure in connection with its IPO on Nasdaq Stockholm

Vinge has advised Verisure plc (“Verisure”) in connection with its IPO on Nasdaq Stockholm. Following the publication of the prospectus on 29 September 2025, trading in Verisure’s shares commenced today, 8 October 2025.
October 08, 2025

Vinge has acted for Advania on the acquisition of smartvokat

smartvokat GmbH, a German-based consultancy specialising in digital transformation within the legal, risk, and compliance domains, will become part of Advania’s business unit Transformation & Automation.
October 08, 2025

Vinge has advised Egetis Therapeutics in connection with a directed share issue

Vinge has advised Egetis Therapeutics AB (publ) (“Egetis Therapeutics”), listed on Nasdaq Stockholm, in connection with a directed share issue whereby Egetis Therapeutics raised proceeds of approximately SEK 183 million before transaction costs.
October 06, 2025